Novel Biomarkers in Inflammatory Bowel Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03833310|
Recruitment Status : Not yet recruiting
First Posted : February 7, 2019
Last Update Posted : March 26, 2019
The inflammatory bowel diseases represent a heterogeneous group of chronic , relapsing- inflammatory disorders of the gastrointestinal tract. Crohn's disease and ulcerative colitis are the two major clinical forms.The global incidence and prevalence of the inflammatory bowel diseases has increased over the last 2-4 decades . Despite the great progress in understanding the pathogenesis of these diseases, their etiology remains unclear . Considerable effort has been devoted to the development of an accurate ,noninvasive biomarkers that have increased diagnostic sensitivity and specificity .
Osteoprotegerin is a member of the Tumor Necrosis Factor Receptor superfamily of proteins. Osteoprotegerin is of particular importance in bone metabolism, inflammation , tumorigenesis, and other processes where cell differentiation, survival, and death are controlled. Osteoprotegerin activates inflammation in the gut by stimulating immune cells, cytokines, and the Necrosis factor-κappaB pathway .
Soluble Receptor activator of nuclear factor kappa-Β ligand is known as a type II membrane protein and as a member of tumor necrosis factor superfamily . Soluble Receptor activator of nuclear factor kappa-Β ligand has been identified to affect the immune system and a binding partner of ( Osteoprotegerin ), and controls cell proliferation.The interactions between Osteoprotegerin and Soluble Receptor activator of nuclear factor kappa-Β ligand, Soluble Receptor activator of nuclear factor kappa-Β have relevance to inflammatory pathways. Soluble Receptor activator of nuclear factor kappa-Β ligand- Soluble Receptor activator of nuclear factor kappa-Β ligand binding activates pathways that contribute to the survival of T-lymphocytes and dendritic cells .
|Condition or disease||Intervention/treatment|
|Inflammatory Bowel Diseases||Diagnostic Test: Osteoprotegerin marker in serum in inflammatory bowel disease|
Show Detailed Description
|Study Type :||Observational|
|Estimated Enrollment :||70 participants|
|Official Title:||Novel Biomarkers in Diagnosis of Inflammatory Bowel Disease|
|Estimated Study Start Date :||June 20, 2019|
|Estimated Primary Completion Date :||August 21, 2021|
|Estimated Study Completion Date :||December 30, 2022|
- Diagnostic Test: Osteoprotegerin marker in serum in inflammatory bowel disease
I will measure Osteoprotegerin and Soluble Receptor activator of nuclear factor kappa-Β ligand markers in serum of patient with inflammatory bowel disease
- level of Osteoprotegerin and sRANKL in newly diagnosed patients with inflammatory bowel disease [ Time Frame: 2 years ]measuring level of Osteoprotegerin and sRANKL in newly diagnosed patients with inflammatory bowel disease then it will measured again after treated with infliximab
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03833310
|Contact: ragaa salama, firstname.lastname@example.org|
|Contact: Amira Abdel Hamid Kamal Mohamed||01068345861||Amira_Kamel222@yahoo.com|
|Principal Investigator:||nesma gamal, demonstrator||Assiut University|